KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2025)

Historic Work In Process for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q4 2025 value amounting to $65.1 million.

  • Alnylam Pharmaceuticals' Work In Process rose 22.16% to $65.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $65.1 million, marking a year-over-year increase of 22.16%. This contributed to the annual value of $65.1 million for FY2025, which is 22.16% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Work In Process of $65.1 million as of Q4 2025, which was up 22.16% from $35.5 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Work In Process ranged from a high of $116.7 million in Q2 2023 and a low of $23.6 million during Q1 2021
  • In the last 5 years, Alnylam Pharmaceuticals' Work In Process had a median value of $73.0 million in 2024 and averaged $73.0 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Work In Process surged by 52506.66% in 2021, and later plummeted by 4918.2% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Work In Process stood at $100.9 million in 2021, then grew by 12.72% to $113.8 million in 2022, then crashed by 32.36% to $77.0 million in 2023, then dropped by 15.57% to $65.0 million in 2024, then grew by 0.22% to $65.1 million in 2025.
  • Its last three reported values are $65.1 million in Q4 2025, $35.5 million for Q3 2025, and $43.8 million during Q2 2025.